UY38386A - Sistema de suministro de polímero líquido para la administración prolongada de fármacos - Google Patents

Sistema de suministro de polímero líquido para la administración prolongada de fármacos

Info

Publication number
UY38386A
UY38386A UY0001038386A UY38386A UY38386A UY 38386 A UY38386 A UY 38386A UY 0001038386 A UY0001038386 A UY 0001038386A UY 38386 A UY38386 A UY 38386A UY 38386 A UY38386 A UY 38386A
Authority
UY
Uruguay
Prior art keywords
liquid polymer
drugs
delivery system
prolonged administration
polymer delivery
Prior art date
Application number
UY0001038386A
Other languages
English (en)
Inventor
Charles MIDDLETON John
Haller Van Hove Amy
Shane GLOVER Garrett
Avinash Nangia
Original Assignee
Tolmar Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar Int Ltd filed Critical Tolmar Int Ltd
Publication of UY38386A publication Critical patent/UY38386A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se dan a conocer composiciones farmacéuticas de polímeros líquidos que comprenden un polímero líquido biodegradable, un sistema solvente biocompatible y un ingrediente farmacéutico activo (API). Las composiciones de la invención son útiles para proporcionar una liberación prolongada y a largo plazo del API.
UY0001038386A 2018-09-25 2019-09-24 Sistema de suministro de polímero líquido para la administración prolongada de fármacos UY38386A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862736182P 2018-09-25 2018-09-25

Publications (1)

Publication Number Publication Date
UY38386A true UY38386A (es) 2020-04-30

Family

ID=68393030

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038386A UY38386A (es) 2018-09-25 2019-09-24 Sistema de suministro de polímero líquido para la administración prolongada de fármacos

Country Status (8)

Country Link
US (1) US20220040201A1 (es)
EP (1) EP3856142A1 (es)
AR (1) AR116501A1 (es)
AU (1) AU2019348739A1 (es)
CA (1) CA3114061A1 (es)
TW (1) TW202027725A (es)
UY (1) UY38386A (es)
WO (1) WO2020065401A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116528876A (zh) * 2020-09-30 2023-08-01 托尔玛国际有限公司 用于延长睾酮的递送的生物可降解聚合物递送系统
CA3197170A1 (en) * 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US20220211660A1 (en) * 2020-10-24 2022-07-07 Mason Cave High viscosity thc product and method of manufacture thereof
US20220125755A1 (en) * 2020-10-24 2022-04-28 Kevin Hazen Cannabis time release apparatus and method of manufacture thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
WO2002038185A2 (en) * 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
CA2530136C (en) * 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
RU2623206C2 (ru) * 2005-04-15 2017-06-22 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
CA2731316C (en) * 2008-08-12 2017-10-03 Novartis Ag Pharmaceutical compositions
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
NZ595973A (en) * 2009-04-24 2014-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
US20140309202A1 (en) * 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
AU2016302252B2 (en) 2015-08-03 2022-01-20 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs

Also Published As

Publication number Publication date
TW202027725A (zh) 2020-08-01
US20220040201A1 (en) 2022-02-10
WO2020065401A1 (en) 2020-04-02
AU2019348739A1 (en) 2021-04-22
EP3856142A1 (en) 2021-08-04
AR116501A1 (es) 2021-05-12
CA3114061A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
UY38386A (es) Sistema de suministro de polímero líquido para la administración prolongada de fármacos
ECSP19075134A (es) Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
BR112018002414A2 (pt) sistema de distribuição de polímero líquido para administração prolongada de fármacos
CY1124037T1 (el) Παρασκευη φορτωμενων με πεπτιδιο μικροσφαιριδιων plga me χαρακτηριστικα ελεγχομενης απελευθερωσης
ECSP17046608A (es) Forma farmacéutica que incluye una solución sólida de drogas amorfas
GEP20217243B (en) Orodispersible dosage unit containing an estetrol component
NZ746573A (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
EA201390783A1 (ru) Биоразлагаемые композиции для доставки лекарственных средств
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
UY31975A (es) Sistema y administración transdérmica de estrógeno
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
CL2017002536A1 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina, métodos y usos de las mismas.
AR113096A1 (es) Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
GEP20217308B (en) Orodispersible dosage unit containing an estetrol component
BR112018077259A2 (pt) formulações depot
AR105223A1 (es) Compuestos químicos
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
UY38593A (es) Formulaciones farmacéuticas que contienen peg, un ingrediente activo y un inhibidor de cristalización
CL2018003682A1 (es) Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos.
CO2024005250A2 (es) Formulaciones y sistemas de erdafitinib para administración intravesical
AR096223A1 (es) Pastilla de nicotina para administración oral